JMA Reps Oppose Reclassification of Epadel OTC despite No Serious ADR Reports: MHLW Safety Panel
To read the full story
Related Article
- Epadel OTC to Be Reclassified as “Class 1” Category under Stricter Rules on Sales: MHLW Panel
April 5, 2019
- At Request of JMA, Pharmacists to Be Required to Confirm that Buyers of Switch OTC Version of Epadel Had Medical Exam Before Purchase
January 15, 2013
- PAC Approves OTC Switching of Epadel
December 21, 2012
- MHLW to Initially Limit Number of Stores to Offer Epadel OTC
October 26, 2012
- PAFSC Committee Recommends Approval for Switch OTC Version of Epadel 2 Years after Frist Review
October 18, 2012
REGULATORY
- MHLW Official Urges Use of New Fund to Drive Reorganization of Generic Sector
August 4, 2025
- MHLW Issues Guidance on Clinical Trial Design for Radiopharmaceuticals
August 4, 2025
- Wage-Based Price Premiums on Drugs Not an Option, Says MHLW Insurance Chief
August 4, 2025
- Japan Panel OKs Taisho’s Insomnia Med, 2 Other NMEs for Approval
August 1, 2025
- MHLW Selects 20 Organizations to Bolster Drug Discovery Clusters
August 1, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…